ADVA
27.4.2021 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-MB , the industry’s first ultra-compact outdoor PTP grandmaster clock with multi-band GNSS receiver and integrated antenna. Part of the OSA 5405 Series of smart synchronization devices for indoor or outdoor deployment, the OSA 5405-MB ensures timing accuracy by eliminating the impact of ionospheric delay variation. This empowers communication service providers (CSPs) and enterprises to deliver the nanosecond precision needed for 5G fronthaul and other emerging time-sensitive applications. The multi-band GNSS receiver and integrated antenna enable the OSA 5405-MB to meet PRTC-B accuracy requirements (+/-40nsec) even in challenging conditions. For the first time, the technology is available in an edge timing device with minimal footprint, helping operators achieve unprecedented accuracy and reliability as they roll out wide-spread small cell networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005060/en/
“Our multi-band, multi-constellation GNSS receiver provides an extremely cost-efficient way to achieve PRTC-B UTC-traceable network timing with the levels of accuracy needed for next-generation use cases. By adding this technology to our versatile, small-form-factor OSA 5405 Series, we’re offering a route to precision synchronization at the network access without significant investment,” said Gil Biran, general manager, Oscilloquartz, ADVA. “A ruggedized design and minimal visibility make our OSA 5405-MB easy to install in almost any outdoor location. With the power to compensate for ionospheric delay variations and provide resilience against jamming and spoofing, our compact edge solution really is the key to 5G synchronization.”
The OSA 5405 Series is a uniquely versatile timing solution ideal for deployment deep in urban canyons, precisely where the most advanced end applications require stringent synchronization. With its small form factor, the OSA 5405-I indoor variant can be positioned on windows to avoid multipath signal interference. Offering both electrical and optical interfaces and featuring cost-effective Ethernet cabling, the OSA 5405 Series avoids the archaic and expensive RF feeds of traditional GNSS installations by integrating an antenna, GNSS receiver and PTP grandmaster in a single device.
Now with multi-band GNSS technology, the OSA 5405-MB also protects against timing inaccuracies caused by ionospheric disturbance. By receiving GNSS signals in two frequency bands and using the differences between them to calculate and compensate for delay variation, the OSA 5405-MB eliminates inaccuracy and ensures ultra-precise synchronization whatever the space weather conditions. It can also work with up to four concurrent GNSS constellations (GPS, GALILEO, GLONASS and BEIDOU), increasing the number of observable satellites in urban canyons. A comprehensive set of Syncjack™ PTP and GNSS jamming and spoofing monitoring features in combination with ADVA’s Ensemble Controller and Sync Director assures highest synchronization quality and provides transparency for simple operation of even very large synchronization networks. The OSA 5405-MB also offers network-delivered timing backup to further mitigate GNSS vulnerabilities and make synchronization more robust and resilient.
“Highly accurate timing is becoming more critical every year. In CSP infrastructure, power utilities, broadcast and enterprise networks across most industries, precision synchronization that meets tight PRTC-B specifications is essential. The OSA 5405-MB is capable of providing different PTP profiles as well as NTP directly out of the smart antenna with no compromise on accuracy,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “With its multi-band receiver, our new OSA 5405-MB delivers PRTC-B levels of synchronization accuracy. Small, lightweight, low-power and versatile, it can be deployed almost anywhere and will perform perfectly even under extreme conditions. What’s more, its Syncjack™ PTP and GNSS assurance capabilities ensure accurate, real-time monitoring of timing quality.”
Further information on the OSA 5405-MB is available in these slides: https://adva.li/osa-5405-mb-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005060/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
